Display options
Cite
Chaudhuri D, Ghate NB, Singh SS, et al. Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacogn Mag. 2015;11(42):269-76doi: 10.4103/0973-1296.153078.
Chaudhuri, D., Ghate, N. B., Singh, S. S., & Mandal, N. (2015). Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacognosy magazine, 11(42), 269-76. https://doi.org/10.4103/0973-1296.153078
Chaudhuri, Dipankar, et al. "Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation." Pharmacognosy magazine vol. 11,42 (2015): 269-76. doi: https://doi.org/10.4103/0973-1296.153078
Chaudhuri D, Ghate NB, Singh SS, Mandal N. Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation. Pharmacogn Mag. 2015 Apr-Jun;11(42):269-76. doi: 10.4103/0973-1296.153078. PMID: 25829764; PMCID: PMC4378123.
Copy Download .nbib Format: NLM
Share it on

Pharmacogn Mag. 2015 Apr-Jun;11(42):269-76. doi: 10.4103/0973-1296.153078.

Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation.

Pharmacognosy magazine

Dipankar Chaudhuri, Nikhil Baban Ghate, Sudhir Shankar Singh, Nripendranath Mandal

Affiliations

  1. Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
  2. Division of Chemistry, TCG Life Sciences Limited, Kolkata, West Bengal, India.

PMID: 25829764 PMCID: PMC4378123 DOI: 10.4103/0973-1296.153078

Abstract

BACKGROUND: Spondias pinnata has been reported for its efficient anticancer effects, but the studies were mostly focused on its extract.

OBJECTIVE: Since its bioactive compounds are largely unknown, this study was designed to characterize the lead components present in it and their anticancer activity against human glioblastoma cell line (U87).

MATERIALS AND METHODS: Major compounds from the ethyl acetate fraction were isolated by column chromatography and their anticancer potentials against U87 cells were evaluated. Furthermore, flow cytometric and immunoblotting analyses were performed to demonstrate the mechanism of apoptosis inducing activity of methyl gallate (MG) against U87 cell line.

RESULTS: Four major compounds were isolated from the ethyl acetate fraction. Amongst these, two compounds showed promising activities and with the help of different spectroscopic methods they were identified as gallic acid and MG. Flow cytometric studies revealed that MG-induced apoptosis in U87 cells dose-dependently; the same was confirmed by activation of caspases through cleavage of endogenous substrate poly (adenosine diphosphate-ribose) polymerase. MG treatment also induced the expression of p53 and B-cell lymphoma-2-associated X and cleavage of BH3 interacting-domain with a concomitant decrease in B-cell lymphoma-2 expression. Moreover, MG-induced sustained phosphorylation of extracellular signal-regulated kinase (ERK1/2) in U87 cells with no change in the phosphorylation of other mitogen-activated protein kinases (c-Jun N-terminal of stress-activated protein kinases, p38).

CONCLUSION: MG is a potent antioxidant and it induces sustained ERK1/2 activation and apoptosis in human glioblastoma U87, and provide a rationale for evaluation of MG for other brain carcinoma cell lines for the advancement of glioblastoma therapy.

Keywords: Anticancer; Spondias pinnata; U87; apoptosis; cytotoxicity; methyl gallate

References

  1. Carcinogenesis. 2002 Jan;23(1):143-50 - PubMed
  2. Ann Intern Med. 1979 Nov;91(5):710-7 - PubMed
  3. J Neurosurg. 1993 May;78(5):767-75 - PubMed
  4. Cytotechnology. 2014 Mar;66(2):209-18 - PubMed
  5. Eur J Pharmacol. 2010 Sep 1;641(2-3):102-7 - PubMed
  6. Oncogene. 1999 Jan 14;18(2):377-84 - PubMed
  7. Cell. 2009 Sep 4;138(5):838-54 - PubMed
  8. Nat Prod Rep. 2000 Jun;17(3):215-34 - PubMed
  9. Genes Dev. 2001 Nov 15;15(22):2922-33 - PubMed
  10. Nat Rev Mol Cell Biol. 2010 Sep;11(9):621-32 - PubMed
  11. Cell. 1995 Jan 27;80(2):293-9 - PubMed
  12. Ann Hepatol. 2013 Jan-Feb;12 (1):123-9 - PubMed
  13. Biochim Biophys Acta. 2013 Aug;1830(8):4017-29 - PubMed
  14. J Immunol. 2010 Dec 1;185(11):6698-705 - PubMed
  15. Curr Opin Oncol. 2001 May;13(3):160-6 - PubMed
  16. Acta Neuropathol. 2005 Jan;109(1):93-108 - PubMed
  17. Phytomedicine. 2000 Mar;7(1):39-47 - PubMed
  18. BMC Complement Altern Med. 2008 Dec 09;8:63 - PubMed
  19. Cancer Biol Ther. 2008 Jul;7(7):1080-9 - PubMed

Publication Types